3C Therapeutics licenses TriCore technology from UBC and iProgen

Under an agreement dated April 29, 2025, 3C Therapeutics holds an exclusive, worldwide license from the University of British Columbia and iProgen Biotech Inc. to develop and commercialize the technology underlying its TriCore platform.

The licensed technology originated from collaborative research involving Professor David Perrin’s laboratory at UBC and scientists at iProgen. The agreement provides the foundation for 3C’s development of degrader-antibody conjugates.